Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Revenue: 2010-2025

Historic Current Deferred Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $3.8 million.

  • Lineage Cell Therapeutics' Current Deferred Revenue fell 54.35% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 54.35%. This contributed to the annual value of $7.4 million for FY2024, which is 31.64% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Current Deferred Revenue stood at $3.8 million, which was down 28.36% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Deferred Revenue peaked at $50.5 million during Q4 2021, and registered a low of $101,000 during Q1 2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $9.1 million (2024), whereas its average is $14.5 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Current Deferred Revenue crashed by 97.88% in 2021, and later soared by 45,048.51% in 2022.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Current Deferred Revenue stood at $50.5 million in 2021, then slumped by 81.34% to $9.4 million in 2022, then climbed by 14.72% to $10.8 million in 2023, then crashed by 31.64% to $7.4 million in 2024, then tumbled by 54.35% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $5.3 million for Q2 2025, and $6.9 million during Q1 2025.